摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4,5-dichloro-2-propyl-pyridazin-3-one | 51659-95-1

中文名称
——
中文别名
——
英文名称
4,5-dichloro-2-propyl-pyridazin-3-one
英文别名
4,5-dichloro-2-n-propyl-3(2H)pyridazinone;4,5-Dichloro-2-propylpyridazin-3(2H)-one;4,5-dichloro-2-propylpyridazin-3-one
4,5-dichloro-2-propyl-pyridazin-3-one化学式
CAS
51659-95-1
化学式
C7H8Cl2N2O
mdl
MFCD02348614
分子量
207.059
InChiKey
NVUOGFPKKSAHIM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.428
  • 拓扑面积:
    32.7
  • 氢给体数:
    0
  • 氢受体数:
    2

SDS

SDS:462244ce07e019c9871ef51c5e16b7c6
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4,5-dichloro-2-propyl-pyridazin-3-one硫酸potassium nitrate 作用下, 反应 8.0h, 以71%的产率得到4,5-dichloro-3-nitro-1-propylpyridazin-6-one
    参考文献:
    名称:
    含哒嗪的新型无环核苷的合成
    摘要:
    本文介绍了一些涉及吡咯并[2,3- c ]哒嗪和4-羟丁基侧链的新型无环核苷的合成。
    DOI:
    10.1002/jhet.5570370102
  • 作为产物:
    描述:
    4,5-二氯-3-羟基哒嗪1-碘代丙烷potassium carbonate 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 2.0h, 以7.31 g的产率得到4,5-dichloro-2-propyl-pyridazin-3-one
    参考文献:
    名称:
    [EN] HERBICIDAL PYRIDAZINONE DERIVATIVES
    [FR] DÉRIVÉS HERBICIDES DE PYRIDAZINONE
    摘要:
    本发明提供了一种式(I)的化合物或其农业上可接受的盐,其中:R2选自由(A1)、(A2)和(A3)组成的群,其中X1为N或CR7,X2为N或CR8,X3为N或CR9,X4为N或CR6,R1、R3、R4、R5、R6、R7、R8和R9如本文所定义。该发明还涉及包括式(I)的化合物的除草剂组合物,以及它们在控制杂草方面的用途,特别是在有用植物作物中。
    公开号:
    WO2013050421A1
点击查看最新优质反应信息

文献信息

  • 3(2H)pyridazinone, process for its preparation and anti-allergic agent
    申请人:Nissan Chemical Industries Ltd.
    公开号:US05098900A1
    公开(公告)日:1992-03-24
    A 3(2H)pyridazinone of the formula: ##STR1## wherein R.sub.1 is C.sub.2 -C.sub.5 alkyl; R.sub.2 is hydrogen, C.sub.1 -C.sub.3 alkyl, chlorine or bromine; R.sub.3 is hydrogen or C.sub.1 -C.sub.4 alkyl; and each of Y.sub.1, Y.sub.2 and Y.sub.3 which may be the same or different, is hydrogen, C.sub.1 -C.sub.8 alkyl, C.sub.2 -C.sub.8 alkenyl, halogen, --(CH.sub.2).sub.l A [wherein A is substituted amino of the formula --N(R.sub.4) (R.sub.5) (wherein each of R.sub.4 and R.sub.5 which may be the same or different, is C.sub.1 -C.sub.4 alkyl, or R.sub.4 and R.sub.5 together form C.sub.4 -C.sub.6 alkylene), morpholino, 4-R.sub.6 -piperazin-1-yl (wherein R.sub.6 is C.sub.1 -C.sub.3 alkyl) or --OR.sub.7 (wherein R.sub.7 is hydrogen or C.sub.1 -C.sub.3 alkyl), and l is an integer of 0 to 3], --OR.sub.8 [wherein R.sub.8 is hydrogen, C.sub.1 -C.sub.8 alkyl, C.sub.3 -C.sub.5 alkenyl, benzyl or --(CH.sub.2).sub.q --R.sub.9 [wherein R.sub.9 is CO.sub.2 R.sub.3 (wherein R.sub.3 is as defined above), --CONHR.sub.3 (wherein R.sub.3 is as defined above) or --CH.sub.2 OR.sub.7 (wherein R.sub.7 is as defined above), and q is an integer of 1 to 5]], --CO.sub.2 R.sub.3 (wherein R.sub.3 is as defined above), --CON(R.sub.10) (R.sub.11) [wherein each of R.sub.10 and R.sub.11 which may be the same or different, is hydrogen, C.sub.1 -C.sub.4 alkyl or C.sub.3 -C.sub.5 alkenyl, or R.sub.10 and R.sub.11 together form C.sub.4 -C.sub.6 alkylene, --(CH.sub.2).sub.2 O(CH.sub.2).sub.2 -- or --(CH.sub.2).sub.2 N(R.sub.6)(CH.sub.2).sub.2 -- (wherein R.sub.6 is as defined above)], --CONH(CH.sub.2).sub.m A (wherein A is as defined above, and m is an integer of 2 to 4), --CH.dbd.CHCOR.sub.12 (wherein R.sub.12 is hydroxy, C.sub.1 -C.sub.4 alkoxy or --N(R.sub.13) (CH.sub.2).sub.n CO.sub.2 R.sub.3 (wherein R.sub.13 is hydrogen, C.sub.1 -C.sub.6 alkyl or cycloalkyl, R.sub.3 is as defined above, and n is an integer of 1 to 4)), --SR.sub.14 (wherein R.sub.14 is C.sub.1 -C.sub.4 alkyl), --CN or ##STR2## wherein R.sub.3 is as defined above), or two of Y.sub.1, Y.sub.2 and Y.sub.3 together form ##STR3## (wherein p is an integer of 1 or 2), and a pharmaceutically acceptable salt thereof.
    一种具有以下结构式的3(2H)吡啶并嗪酮化合物:其中R.sub.1是C.sub.2 -C.sub.5烷基;R.sub.2是氢、C.sub.1 -C.sub.3烷基、氯或溴;R.sub.3是氢或C.sub.1 -C.sub.4烷基;以及Y.sub.1、Y.sub.2和Y.sub.3中的每一个(可以相同也可以不同)是氢、C.sub.1 -C.sub.8烷基、C.sub.2 -C.sub.8烯基、卤素、--(CH.sub.2).sub.l A(其中A是具有以下结构式的取代氨基:--N(R.sub.4)(R.sub.5)(其中R.sub.4和R.sub.5可以相同也可以不同,为C.sub.1 -C.sub.4烷基,或R.sub.4和R.sub.5一起形成C.sub.4 -C.sub.6烷基)、吗啉基、4-R.sub.6-哌嗪-1-基(其中R.sub.6为C.sub.1 -C.sub.3烷基)或--OR.sub.7(其中R.sub.7为氢或C.sub.1 -C.sub.3烷基),l为0到3的整数,--OR.sub.8(其中R.sub.8为氢、C.sub.1 -C.sub.8烷基、C.sub.3 -C.sub.5烯基、苄基或--(CH.sub.2).sub.q --R.sub.9(其中R.sub.9为CO.sub.2R.sub.3(其中R.sub.3如上定义)、--CONHR.sub.3(其中R.sub.3如上定义)或--CH.sub.2OR.sub.7(其中R.sub.7如上定义),q为1到5的整数)],--CO.sub.2R.sub.3(其中R.sub.3如上定义),--CON(R.sub.10)(R.sub.11)(其中R.sub.10和R.sub.11可以相同也可以不同,为氢、C.sub.1 -C.sub.4烷基或C.sub.3 -C.sub.5烯基,或R.sub.10和R.sub.11一起形成C.sub.4 -C.sub.6烷基、--(CH.sub.2).sub.2O(CH.sub.2).sub.2--或--(CH.sub.2).sub.2N(R.sub.6)(CH.sub.2).sub.2--(其中R.sub.6如上定义),--CONH(CH.sub.2).sub.m A(其中A如上定义,m为2到4的整数),--CH.dbd.CHCOR.sub.12(其中R.sub.12为羟基、C.sub.1 -C.sub.4烷氧基或--N(R.sub.13)(CH.sub.2).sub.nCO.sub.2R.sub.3(其中R.sub.13为氢、C.sub.1 -C.sub.6烷基或环烷基,R.sub.3如上定义,n为1到4的整数),--SR.sub.14(其中R.sub.14为C.sub.1 -C.sub.4烷基),--CN或(其中R.sub.3如上定义),或Y.sub.1、Y.sub.2和Y.sub.3中的两个一起形成(其中p为1或2)的结构式,以及其药用盐。
  • Retro-ene reaction. II. Reaction of 4,5-dichloro-1-hydroxy-methylpyridazin-6-one with alkyl halides and carboxylic acid chlorides
    作者:Sung-Kyu Kim、Su-Dong Cho、Deok-Heon Kweon、Sang-Gyeong Lee、Joo-Wha Chung、Sung Chul Shin、Yong-Jin Yoon
    DOI:10.1002/jhet.5570330205
    日期:1996.3
    thylcarboxylates were synthesized from 4,5-dichloro-1-hydroxymethylpyridazin-6-one and the corresponding alkyl halides or carboxylic acid chlorides. Also the reaction mechanisms via a fragmentation of retro-ene type are discussed.
    由4,5-二氯-1-羟甲基哒嗪-6-一和相应的烷基合成1-烷基-4,5-二氯哒嗪-6-oncs和(4,5-二氯-6-氧杂哒嗪-1-基)甲基羧酸酯。卤化物或羧酸氯化物。还讨论了通过逆烯型断裂的反应机理。
  • Synthesis of alkyl or aryl pyridazinyl ethers
    作者:Hyun-A Chung、Jeum-Jong Kim、Ho-Kyun Kim、Deok-Heon Kweon、Sang-Gyeong Lee、Yong-Jin Yoon、Su-Dong Cho
    DOI:10.1002/jhet.5570420425
    日期:2005.5
    This paper presents the synthesis of some alkyl or aryl pyridazinyl ethers from 2-alkyl-4-halo-5-hydroxy-and 2-alkyl-4,5-dichloropyridazin-3(2H)-ones or 3,6-dichloropyridazine. Reaction of 2-alkyl-4-halo-5-hydroxypyridazin-3(2H)-ones 1 with 1,2-dibromoethane or 1,3-dibromopropane gave the corresponding monopyridazin-5-yl ethers 2 and α,ω-[di(pyridazin-5-oxy)]alkanes 3. Treatment of 4 with 4-substituted-phenol
    本文提出了由2-烷基-4-卤代-5-羟基-和2-烷基-4,5-二氯哒嗪-3(2 H)-或3,6-二氯哒嗪合成一些烷基或芳基哒嗪基醚的方法。2-烷基-4-卤代-5-羟基哒嗪-3(2 H)-ones 1与1,2-二溴乙烷或1,3-二溴丙烷的反应给出了相应的单哒嗪-5-基醚2和α,ω-[二(哒嗪-5-氧基)]烷烃3。用4-取代的苯酚处理4,得到5-(4-取代的苯氧基)-2-(4-取代的苯氧基甲基)衍生物5。2-烷基-4,5-二氯衍生物7与1的反应生成相应的二(哒嗪-5-基)醚8丰产。使化合物10与邻苯二酚反应,得到单哒嗪-3-基醚11和/或二(哒嗪-3-基)醚12。我们还描述了2-烷基-4-氯-5-(4-取代-苯氧基)哒嗪-3(2 H)-one与亲核试剂反应的结果。
  • An Efficient and Practical Method for the Synthesis of 1-(2,6-Difluorobenzoyl)-3-(2-alkyl-3-oxopyridazin-4-yl)ureas as Potential Chitin Synthesis Inhibitors
    作者:Song Cao、De-Li Lu、Chuan-Meng Zhao、Li-Na Li、Qing-Chun Huang、Xu-Hong Qian
    DOI:10.1007/s00706-005-0476-7
    日期:2006.6
    A mild and efficient method for the synthesis of 4-amino-3(2 H )-pyridazinones from their corresponding 4,5-dichloropyridazinones under microwave-assisted conditions is described. A series of novel chitin synthesis inhibitors, benzoylphenylureas containing the 3(2 H )-pyridazinone, were synthesized. The biological activity of these target compounds was evaluated.
    描述了一种在微波辅助条件下由其相应的4,5-二氯吡啶并酮合成4-氨基-3(2 H )-哒嗪酮的温和有效方法 。合成了一系列新型的几丁质合成抑制剂,含有3(2 H )-哒嗪酮的苯甲酰基苯基脲 。评价了这些目标化合物的生物活性。
  • Concurrent alkylation-methoxylation of 4,5-dihalopyridazin-6-ones and synthesis of 5-halo-4-hydroxypyridazin-6-ones
    作者:Su-Dong Cho、Woo-Yong Choi、Yong-Jin Yoon
    DOI:10.1002/jhet.5570330605
    日期:1996.11
    1-Alkyl-5-halo-4-methoxypyridazin-6-ones were synthesized from 1-alkyl-4,5-dihalopyridazin-6-ones by the concurrent alkylation-methoxylation. 1-Alkyl-5-halo-4-hydroxypyridazin-6-ones were also prepared.
    通过同时进行的烷基化-甲氧基化反应,由1-烷基-4,5-二卤代哒嗪-6-酮合成了1-烷基-5-卤代-4-甲氧基哒嗪-6-酮。还制备了1-烷基-5-卤代-4-羟基哒嗪-6-。
查看更多